Home Daily Stock Opinions and Ratings Viatris (VTRS-Q)

Trending stocks today

Crescent Point Energy Corp Rogers Communications (B) Pfizer Inc Minto Apartment REIT Winpak Ltd. Cenovus Energy Headwater Exploration Inc. Whitecap Resources Mainstreet Equity Corp Parex Resources Inc. Visa Inc. Canadian Pacific Rail Canadian Natural Rsrcs Zscaler Inc. VMware Inc. PVH Corp Nike Inc Verizon Communications CCL Industries (B)

Viatris (VTRS-Q)

63 watching

NASDAQ:VTRS

9.33
0.15 (1.63%) 1d
Jun 2, 2023, 8:00 pm
0
RISKY

Viatris(VTRS-Q)

14/04/2023
Viatris

Product of recent merger of two separate pharma business'.
New CEO - remains to be seen whether he will preform.
Would like to see stabilization on business before investing.
Too early to invest. 

Pharma & Healthcare
Michael Hakes - CFA, MBA
$9.850
No
UnlockRating
TOP PICK

Viatris(VTRS-Q)

13/03/2023
Viatris

It is the cheapest stock in their portfolio at 4X earnings, a pharma company formed by a joint venture. Its investment grade bond issues are in rock solid shape. It sold a division for $2 billion and will use the cash for a couple of acquisitions in eye wear and to buy back stock. There are potential sales of other smaller divisions so there could be more buybacks plus paying down debt. The dividend yield is 4.1%. Has a low price due to a couple of disappointing quarters but numbers have been solid since. Also revenues have been flat-lining.
Buy 4   Hold 10   Sell 0

(Analysts’ price target is $13.09)
Pharma & Healthcare
Lorne Steinberg
$9.870
Owned
UnlockRating
DON'T BUY

Viatris(VTRS-Q)

01/03/2023
Viatris

Global healthcare, mix of branded drugs and generics. Drug business has had a good run, but there's going to be significant pushback on the outsized profits, both globally and in the US. He prefers medical devices.

Pharma & Healthcare
Brendan Caldwell
$11.320
No
UnlockRating
PAST TOP PICK

Viatris(VTRS-Q)

23/01/2023
Viatris
(A Top Pick Jan 27/22, Down 17%) It sold a division for $2 billion with a chunk of that money going to the purchase of a couple of eye-care companies. It is trading at 4X earnings and buying back lots of stock. It covers a number of areas including oncology, the central nervous system, anesthetics and will narrow this down to areas such as diabetes and cardio vascular which have good growth ahead of them.
Pharma & Healthcare
Lorne Steinberg
$11.820
Owned
UnlockRating
BUY

Viatris(VTRS-Q)

01/11/2022
Viatris
Pharmaceutical company that sells generic drugs. Healthy dividend yield and cash flow. About to close on M&A deal. Big question is whether company will return capital to shareholders (share buybacks). Shares very cheap at current price.
Pharma & Healthcare
Lorne Steinberg
$10.235
Owned
UnlockRating
HOLD

Viatris(VTRS-Q)

25/08/2022
Viatris
Trading at 4x earnings. Disappointed Wall Street. Finally stabilized earnings. Asset sale later this year will bring in a fair bit of money. He anticipates a share buyback, decent cashflow, decent dividend to continue. Strategy becoming more apparent.
Pharma & Healthcare
Lorne Steinberg
$10.155
Owned
UnlockRating
BUY

Viatris(VTRS-Q)

26/07/2022
Viatris
Later this year they will complete the sale of a business and the company could (probably) buy back 10% of shares with that cash. Be patient. Trades at only 3-4x earnings. So a buyback will be a big boost to shares. Early on their reports disappointed but lately has been alright. This flies under the radar.
Pharma & Healthcare
Lorne Steinberg
$9.895
Unknown
UnlockRating
BUY

Viatris(VTRS-Q)

21/06/2022
Viatris
It's the cheapest stock he owns, trading at 3x earnings. They generate fresh cash flow. They close the sale in late 2022 of one of their divisions. He expects them to use a major share buyback with those proceeds, and a bump in the share price finally. This is an incredible value stock or everybody is missing something. We'll see.
Pharma & Healthcare
Lorne Steinberg
$10.600
Owned
UnlockRating
DON'T BUY

Viatris(VTRS-Q)

12/05/2022
Viatris
Once they spun out their biosimilar business, he sold. Saw lots of debt, drugs coming off patent and pricing pressure, not a lot of growth. Value trap, even at these levels.
Pharma & Healthcare
Paul MacDonald
$10.750
No
UnlockRating
HOLD

Viatris(VTRS-Q)

11/05/2022
Viatris
Underperformer. Profitable, free cashflow positive. Out of favour. Profits from sale of biosimilar business will be used to buy back shares, which he approves of. Compellingly cheap at 3x earnings. Paying down debt.
Pharma & Healthcare
Lorne Steinberg
$10.455
Owned
UnlockRating
HOLD

Viatris(VTRS-Q)

06/04/2022
Viatris
Cheapest stock in his portfolio, at a PE of 4. Free cashflow and dividend payer. Market didn't like lukewarm guidance. Either he's missing something, or it won't take much for the stock to outperform.
Pharma & Healthcare
Lorne Steinberg
$10.650
Owned
UnlockRating
DON'T BUY

Viatris(VTRS-Q)

03/02/2022
Viatris
Includes boring drugs, which provide consistent cashflows. Bit of growth in its biosimilar business, but talk of selling that. Range bound, limited growth, fair amount of debt, but tolerable for the type of assets. Low margin generics are more sensitive to inflationary risks. Dividend is probably safe.
Pharma & Healthcare
Paul MacDonald
$15.130
No
UnlockRating
TOP PICK

Viatris(VTRS-Q)

27/01/2022
Viatris
Huge free cashflow. PE ratio is 4, not 14, but 4. Stock disappointed investors last year, Q3 was above expectations, expects Q4 to be strong. Needs very little to go right for them to do well. Went up in the recent down market. How can you not buy it? Yield is 3.25%. (Analysts’ price target is $18.62)
Pharma & Healthcare
Lorne Steinberg
$14.775
Owned
UnlockRating
DON'T BUY

Viatris(VTRS-Q)

03/01/2022
Viatris
Among the biggest losers on the S&P in 2021 #6, down 28%. It's a Pfizer generic drug spin-off. Bad timing--Biden wants to reign in generic drug pricing. VTRS expects no earnings growth this year or next. They hold patent drugs under pressure as more knock-offs hit the market. It's the ultimate value trap. It sells for less than 4x earnings, but this is usually a red flag. Better to buy big pharmas.
Pharma & Healthcare
Jim Cramer - Mad Money
$14.230
No
UnlockRating
PAST TOP PICK

Viatris(VTRS-Q)

22/12/2021
Viatris
(A Top Pick Dec 22/20, Down 24%) By far the cheapest cost (and highest value) stock in their portfolio. A fist banging buy. They have drugs like the EpiPen and others for asthma. They pay a reasonable dividend and it trades at 4x earnings. Even at 8x, it would be very cheap. He is not concerned about legal issues surrounding the EpiPen - you simply need their product.
Pharma & Healthcare
Lorne Steinberg
$13.300
Owned
UnlockRating
Showing 1 to 15 of 21 entries
Next PageNext Page

Viatris(VTRS-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 5

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 7

Stockchase rating for Viatris is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Viatris(VTRS-Q) Frequently Asked Questions

What is Viatris stock symbol?

Viatris is a American stock, trading under the symbol VTRS-Q on the NASDAQ (VTRS). It is usually referred to as NASDAQ:VTRS or VTRS-Q

Is Viatris a buy or a sell?

In the last year, 7 stock analysts published opinions about VTRS-Q. 5 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Viatris.

Is Viatris a good investment or a top pick?

Viatris was recommended as a Top Pick by on . Read the latest stock experts ratings for Viatris.

Why is Viatris stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Viatris worth watching?

7 stock analysts on Stockchase covered Viatris In the last year. It is a trending stock that is worth watching.

What is Viatris stock price?

On 2023-06-02, Viatris (VTRS-Q) stock closed at a price of $9.33.

You may also like:

STOR-N LAF-T EMC-T CVR-X RBAK-Q KWE-X ETR-N BHF-Q ADCT-Q IPSU-Q

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Get Access To Watchlist

Latest Buy Signals

AAPL-QApple Inc
Apple Inc
$180.95
0.86 (0.47%)
ET-NEnergy Transfer LP
Energy Transfer LP
$12.88
0.28 (2.13%)
MMSI-QMerit Medical Systems
Merit Medical Systems
$84.35
1.46 (1.70%)
TWNK-QHostess Foods
Hostess Foods
$26.24
1.05 (3.85%)
SOFI-QSoFi Technologies
SoFi Technologies
$7.03
0.21 (2.90%)
Advertising

Today's Top Picks

CCL.B-TCCL Industries (B)
CCL Industries (B)
$63.18
0.48 (0.75%)
VZ-NVerizon Communications
Verizon Communications
$34.58
-1.14 (-3.41%)
NKE-NNike Inc
Nike Inc
$107.78
4.49 (4.00%)
PVH-NPVH Corp
PVH Corp
$77.64
-0.18 (-0.23%)
VMW-NVMware Inc.
VMware Inc.
$133.94
-2.35 (-1.79%)

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

SAVA-QCassava Sciences
Cassava Sciences
$23.04
0.52 (2.21%)
LAZR-QLuminar Technologies
Luminar Technologies
$6.86
-0.04 (-0.59%)
AI-NC3.ai, Inc.
C3.ai, Inc.
$32.36
-2.37 (-7.89%)
S-NSentinelOne Inc.
SentinelOne Inc.
$13.44
-7.28 (-118.18%)
OKTA-QOkta, Inc.
Okta, Inc.
$73.83
-0.86 (-1.18%)

Most Recent Experts

Stockchase

Stockchase Insights

5i Research

Cramer

Jim Cramer - Mad Money

CNBC

Gardner

Brianne Gardner

Raymond James

Curry

Zachary Curry

Davis-Rea Ltd.

Panic-Proof (Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Advertising
Advertising
logoTop pickslogoStockslogoRecentlogoWatchlist
© Stockchase Inc.